Microbix Biosystems Inc. · TSX:MBX
Microbix Biosystems — Investor Presentation (September 2022)
24 slides from Microbix Biosystems's investor presentation, Sep 19, 2022
Slide 1: Infectious Disease Testing Specialists Corporate Presentation
Infectious Disease Testing Specialists Corporate Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements • This presentation contains forward-looking statements about trends and objectives. • Risks and uncertainties related to such statements could cause actual outcomes to differ materially. • Such risks include, among others, those related to operations, customers or markets
Slide 3: Our Company Today
MICROBIX BIOSYSTEMS INC. Our Company Today Develops, makes, and sells biological International leader in supplying products for human health, with over 100 native “antigens”, as a critical part of skilled employees and sales approaching medically important infectious C$2.0M per month. disease tests.
Slide 4: Microbix Senior Management
Microbix Senior Management Cameron L. Groome Jim Currie, CPA Ken Hughes, Ph.D. CEO, President, and Director Chief Financial Officer Chief Operating Officer • Has served on the MBX BoD and AC since • Joined MBX as CFO in 2016 after • Executive and biomedical scientist with 25 2012, and was appointed
Slide 5: Microbix Board of Directors
Microbix Board of Directors Martin Marino Dr. Peter M. Blecher Mark A. Cochran, Ph.D. Board Chairman Director HRGC Chair • Mr. Marino has more than 30 years’ • Dr. Blecher worked as an Emergency Room • Dr. Cochran was Executive Director of Johns experience in corporate legal roles and physician for
Slide 6: Microbix Capital Structure
Microbix Capital Structure 0.9 3000000 0.8 2500000 0.7 0.6 2000000 0.5 1500000 0.4 0.3 1000000 0.2 500000 0.1 0 0 1/16/20 2/16/20 7/16/20 8/16/20 9/16/20 7/16/21 8/16/21 9/16/19 3/16/20 4/16/20 5/16/20 6/16/20 1/16/21 2/16/21 3/16/21 4/16/21 5/16/21 6/16/21 9/16/21 1/16/22 2/16/22 3/16/22 4/16/22 5/
Slide 7: Microbix's Three Sales-Driven Business Divisions @ ~C$ 20M Ttl
Microbix’s Three Sales-Driven Business Divisions @ ~C$ 20M Ttl Current platform and capacity enables accelerating sales growth by a well-established multi-product life sciences business QAPs for EQA/PT DxTM Medium for Global leader in native agencies, Dx OEMs, and Specimen Collection antigen product
Slide 8: Microbix's Manufacturing Capabilities
Microbix’s Manufacturing Capabilities Our Three Facilities Provide Capacity & Flexibility QAPs @ 235 Watline Antigens @ 265 Watline DxTM @ 275 Watline • 10, 000 ft2 • 14, 000 ft2 • 10, 000 ft2 • Semi-automated and automated • Core antigen production systems • Initial capacity at 100,000 DxTM QAPs pr
Slide 9: Microbix's Three Sales-Driven Business Divisions
Microbix’s Three Sales-Driven Business Divisions Some of our many customers or collaborators 01 QAPs™ 02 DxTM™ 03 Native Antigens 9
Slide 10: 01. Quality Assessment Products: Helping Ensure Test Accuracy
01. Quality Assessment Products Helping Ensure Test Accuracy Microbix identified an important role for its expertise → The QAPs™ Opportunity beyond antigens for immunoassays: For Quality Assessment Products (QAPs™). Proper Quality Control (QC) of infectious disease tests is critical to health outcom
Slide 11: The QAPs Product Line & Our Objectives
01. Quality Assessment Products The QAPs™ Product Line & Our Objectives Microbix is continuing to expand its line of QAPs. Includes both liquid vial and FLOQSwab® formats. Already comprises >80 discrete SKUs. QAPs have competitive advantages 1. Performance – QAPs are whole- 2. Formats – Having vials
Slide 12: Our QAPs Segments and their Markets
01. Quality Assessment Products Our QAPs Segments and their Markets • Licensed/ registered for sale in Canada, EU and U.S. (vial and/or swab formats) C$ 10s of millions in sales targeted – • Sold directly to clinical lab chains or via distributors (via 9 Cos., into 30+ countries) >US$ 30/unit MRSP,
Slide 13: ~$5M/Year was just the start for QAPs
01. Quality Assessment Products ~$5M/Year was just the start for QAPs™ PROCEEDx™ – For qualifying new REDx Controls™ – To support the formal QC instruments and training technicians and QA programs of clinical laboratories To Dx OEMs, Labs, & Distributors To Clinical Labs & Distributors Sales began i
Slide 14: DxTM Viral Transport Medium (VTM)
02. VTM for Ontario & others DxTM™ Viral Transport Medium (VTM) Specific Microbix Activities: → Why this Project? Identified Need of Ontario Applied to OTF Program Outreach to MEDJCT Project Selected by Ontario Expertise in large-scale biological Security of supply being key Supported due diligence
Slide 15: Viral Transport Medium (VTM)
02. VTM for Ontario & others Viral Transport Medium (VTM) Every PCR test conducted requires a vial of VTM, all of which was imported. Sales Potential for VTM VTM needs expected to continue, driven by both respiratory viruses and the ongoing need to test for many other infectious organisms. • Microbi
Slide 16: Sales of Antigens for Immunoassays
03. Antigens Sales of Antigens for Immunoassays Immunoassays Antigens Diagnostic tests that measure an antigen-antibody Any foreign substance that evokes an antibody response reaction, and for infectious diseases, can: and binds to an antibody. Antigens are an essential and a) suggest the presence o
Slide 17: Growth Outlook for Antigens Business
03. Antigens Growth Outlook for Antigens Business As healthcare re-stabilizes, Antigen sales may benefit from greater Antigens comprise <50% of global attention to respiratory and infectious disease testing as a total sales, changed from 90% result of the COVID-19 pandemic. historically due to growt
Slide 18: Fiscal 2021 Results
04. Financials Fiscal 2021 Results COVID-19 changed sales for antigens and QAPs, while creating its own opportunities. • Microbix has created & launched leading products with its new QAPs & VTM. • In fiscal 2021, QAPs sales growth overcame the slowdown in antigen sales, with record sales of $18.6M &
Slide 19: Financial Results – 2017 to 2022 YTD
04. Financials Financial Results – 2017 to 2022 YTD Revenue Gross Margin 20,000,000 12,000 100% 10,000 80% 15,000,000 8,000 60% 10,000,000 6,000 40% 5,000,000 4,000 2,000 20% 0 0 0% 2017 2018 2019 2020 2021 YTD 2022 2017 2018 2019 2020 2021 YTD 2022 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Gross Margin (%) Financial
Slide 20: Comparables & Valuation
04. Financials Comparables & Valuation Company Est. Ticker Currency Price Market Cap EV EV/Revenue EV/EBITDA iA Capital Markets has a BUY Meridian Bioscience Inc. Source Con NASDAQ: VIVO USD $32.06 (M) $1,402.6 (M) $1,350.9 2021A 4.2 2022E 4.0 2023E 4.4 2021A na 2022E na 2023E na rating and a 12-mon
Slide 21: Investment Highlights & Catalysts
04. Financials Investment Highlights & Catalysts Strong Annual Sales Growth Record year in F2021, Record YTD F2022 Generating positive Cash Improving Gross Margins across Flow from Operations all product lines Well-capitalized for facility Growing QAPs offerings (to >80 improvements, automation, pro
Slide 22: Thank You
THANK YOU Corporate Presentation Cameron Groome CEO, President, and Director cameron.groome@microbix.com 22
Slide 23: Kinlytic Urokinase: Partnering Opportunity
05. Kinlytic® Urokinase Partnering Opportunity → Kinlytic® Urokinase Specific Kinlytic Activities: Microbix’s expertise in biologicals Refined Project Scope Established Precise Costs led to its securing rights to this Catheter Clearance Indication Quotes from qualified vendors clot-buster drug, whic
Slide 24: Kinlytic Urokinase: Partnering Opportunity
05. Kinlytic® Urokinase Partnering Opportunity The U.S. return of Kinlytic Clearing blood clots from I.V. → Kinlytic® Urokinase catheters is now a >US$350 million starts with its FDA-approved Urokinase is a human protein use for catheter clearance. monopoly in the USA, held by tPA that dissolves blo
Microbix Biosystems — Investor Presentation (September 2022) on 6ix